Xiaoshuai Zhang
Beijing Key Laboratory Of Hematopoietic Stem Cell Transplantation
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia?
Journal: Cytometry. Part B, Clinical cytometry
Published: October 27, 2025
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.
Journal: Haematologica
Published: December 04, 2024
Is there really an accelerated phase of chronic myeloid leukaemia at presentation?
Journal: Leukemia
Published: June 09, 2024
Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia.
Journal: Cancer
Published: April 28, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 19, 2024
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy.
Journal: Leukemia
Published: April 16, 2023
Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
Journal: Annals of hematology
Published: March 20, 2023
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Journal: American journal of hematology
Published: March 13, 2023
Showing 1-10 of 10
Last Updated: 09/26/2026